<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485962</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_Fibr(Burns)</org_study_id>
    <nct_id>NCT04485962</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Skin Burns Using Keratinocytes and Skin Fibroblasts</brief_title>
  <official_title>Treatment of Patients With Skin Burns Using Autologous Keratinocytes and Skin Fibroblasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian Medical Academy of Post-Graduate Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with burns of the skin of the 2nd degree using: autologous
      keratinocytes and skin fibroblasts mixed with collagen gel 7% (tissue equivalent of the skin)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of patients with burns of the skin of the 2nd degree by applying a wound covering
      with layer-by-layer cultured autologous keratinocytes and fibroblasts in collagen gel
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cured patients</measure>
    <time_frame>1 month</time_frame>
    <description>Number of patients cured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Cell application related adverse events assessed by blood count, liver and function tests</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Fibroblasts and keratinocytes treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibroblasts and keratinocytes treated patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibroblasts and keratinocytes</intervention_name>
    <description>Autologous cultured fibroblasts and keratinocytes
For PR: The name &quot; fibroblasts and keratinocytes&quot; is exactly the name of the cell product registered by our ministry of health. There is no trade or international name.</description>
    <arm_group_label>Fibroblasts and keratinocytes treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  skin burns of the 2nd degree

        Exclusion Criteria:

          -  acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis

          -  mental disorders

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Volotovski, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Head of the Lab of Institute of Biophysics and Cell Engineering</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Podgaiskiy, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Head of the plastic surgery and combustiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexey Chasnoit, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dean of the plastic surgery and combustiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zinaida Kvacheva, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lead Researcher of Institute of Biophysics and Cell Engineering</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>burns</keyword>
  <keyword>fibroblasts</keyword>
  <keyword>keratinocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

